Catalyst Biosciences, Inc.
(NASDAQ : CBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%176.301.2%$600.82m
GILDGilead Sciences, Inc.
0.62%68.020.9%$542.46m
BIIBBiogen Inc.
-0.06%280.401.2%$519.30m
CELGCelgene Corporation
-2.01%78.371.2%$513.71m
REGNRegeneron Pharmaceuticals, Inc.
-2.01%301.812.6%$316.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.07%121.072.0%$253.26m
ILMNIllumina, Inc.
0.45%269.673.5%$244.32m
VRTXVertex Pharmaceuticals Incorporated
0.58%157.241.9%$236.54m
NKTRNektar Therapeutics
7.66%85.306.0%$212.18m
AAgilent Technologies, Inc.
1.15%64.321.5%$199.05m
INCYIncyte Corporation
1.79%67.832.5%$194.51m
SRPTSarepta Therapeutics, Inc.
1.78%93.4816.6%$131.29m
EXASExact Sciences Corporation
2.43%52.3625.5%$116.06m
BMRNBioMarin Pharmaceutical Inc.
0.51%88.884.4%$114.43m
ALNYAlnylam Pharmaceuticals, Inc
1.15%102.819.8%$103.66m

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. The company was founded on August 5, 2002 and is headquartered in South San Francisco, CA.